OpenAI has a new AI model designed for biology and science

OpenAI’s latest AI model is designed to do more than just provide cooking tips or create a spreadsheet. GPT-Rosalind, the company’s first model designed specifically for life sciences, aims to help scientists in drug discovery, biology and translational medicine.

The model is named Rosalind Franklinwhose research revealed the structure of DNA and formed the foundations of modern molecular biology. Scientific research relies heavily on data, and GPT-Rosalind is designed to help sort through it, while also helping to reduce the time it takes for new drugs to be developed, approved and brought to market.

(Disclosure: Ziff Davis, the parent company of CNET, in 2025 filed a lawsuit against OpenAI, alleging that it infringed Ziff Davis’s copyrights in training and operating its AI systems.)

It can take 10 to 15 years for a new drug to be developed and approved in the United States. OpenAI said in a blog post on Thursday. GPT-Rosalind aims to improve the selection of research targets and generate stronger hypotheses for higher quality experiments.

The model has been tested on topics such as its understanding of organic chemistry, proteins and genetics. Researchers can use it to find scientific literature relevant to their work or design experiments.

This is not the first time an AI model has been developed with medical advances in mind. Google DeepMind It has developed several AI models for scientific research, such as AlphaFold, which has earned its creators a share of Nobel Prize in Chemistry 2024.

“For me, the best use case for AI has been improving human health and accelerating scientific discoveries,” Demis Hassabis, CEO of Google DeepMind, said in an article. The last interview. Anthropic foot Claude Life Sciences In January for the same purpose.

Some scientists have expressed concerns in the past about how quickly AI will penetrate the scientific space He warned of vulnerabilities and potential misuse and issues related to data representation.

OpenAI said GPT-Rosalind has safeguards to protect it from misuse — such as creating a bioweapon — and has collaborated with several biotech, pharmaceutical and life sciences organizations to support scientific research and discovery.

“Our unique collaboration with OpenAI enables us to apply their most advanced capabilities and tools in new and innovative ways with the potential to accelerate how we deliver medicines to patients,” Sean Bruitsch, senior vice president of artificial intelligence and data at biopharmaceutical company Amgen, said in a statement that scientific work requires rigor.

GPT-Rosalind is only available through OpenAI Trusted Access System As a research introduction.